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The present study has focused on the isolation and structure determination of phenanthrenes from
Juncus atratus Krock. Nine compounds, among them ﬁve phenanthrenes, have been isolated from the
methanol extract of the plant. Two compounds [juncatrins A (1) and B (2)] are new natural products,
three phenanthrenes [juncuenin B (3), effusol (4), and dehydroeffusol (5)], the ﬂavones apigenin (7) and
luteolin (8), the diterpene phytol and 13(R)-hydroxy-octadeca-(9Z,11E,15Z)-trien-oic acid (9) were iso-
lated for the ﬁrst time from the plant. Juncatrin A (1) is substitued with an acetyl group, while in case of
juncatrin B (2), an unprecedented acetylene group is connected to the phenanthrene skeleton. The
isolated phenanthrenes were evaluated for their antiproliferative activity against HeLa, SiHa and MDA-
MB-231 human tumor cell lines. Four phenanthrenes (2, 3, 4 and 5) were more effective [IC50s
3.48 mM (2), 2.91 (3), 3.68 (4), and 7.75 mM (5)] than cisplatin (IC50 12.43 mM) on HeLa cells.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
The ﬁrst isolation of phenanthrenes from natural source dates
back to the 1960's, and till that time more than 450 compounds
were identiﬁed from different plant families. The richest sources of
phenanthrenes are the members of the family Orchidaceae, Jun-
caceae, Combretaceae, and Dioscoreaceae [1].
Juncus is the largest and by far the most important genus of
family Juncaceae from phytochemical and pharmacological points
of view. Various Juncus species (e.g. J. effusus, J. inﬂexus, J. rigidus,
J. conglomeratus) are used in traditional medicines for the treat-
ment of numerous disorders (e.g. anxiety, insomnia, painful uri-
nation, fever, inﬂammation, skin diseases, pharyngitis, and aphtha).
Medulla Junci, the dried stem pith of J. effusus, is ofﬁcial in the
Pharmacopoeia of the People's Republic of China (2005) [2].
According to the literature data, the major bioactive compo-
nents of Juncaceae species are phenanthrenes. Almost 20% of
currently known natural phenanthrenes were described from
Juncus species (Juncus acutus, J. effusus, J. inﬂexus, J. maritimus,gnosy, University of Szeged,
sas).J. roemerianus, J. setchuensis, and J. subulatus). These compounds are
important chemotaxonomic markers, as the presence of a vinyl
group in the molecule is characteristic only for Juncaceae phen-
anthrenes [3,4]. Monomers and dimers are also isolated from Jun-
cus species. The most common substituents of Juncus
phenanthrenes are methyl, hydroxy, and methoxy groups, but
carboxyl-, formyl-, methoxyethyl-, ethoxyethyl-, hydroxyethyl-,
oxymethylene- and aldehyde-substituted, and glycosylated com-
pounds were also referred. The most important pharmacological
effects of these phenanthrenes are the antiproliferative, anti-
inﬂammatory, antioxidant, antimicrobial, and spasmolytic activ-
ities. [4,5].
In continuation of our work dealing with the isolation of bio-
logically active secondary metabolites from Juncaceae species,
Juncus atratus Krock. was investigated. J. atratus is a rare herbaceous
perennial in Central European ﬂoodplains that has long been
known to occur in disturbed habitat patches [6]. This plant has not
been investigated previously.2. Results and discussion
The dried and ground whole plant material was extracted with
methanol at room temperature. After evaporation, the extract was
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was performedwith CH2Cl2 and EtOAc. The dichloromethane phase
was puriﬁed by a combination of different methods, including CC,
VLC, gel ﬁltration, preparative TLC, and HPLC to afford 9 compounds
(Fig. 1).
The structure determination was carried out by extensive
spectroscopic analysis, using 1D and 2D NMR (1H-1H COSY, HSQC,
HMBC, NOESY) spectroscopy, HRESIMS and comparison of the
spectral data with literature data.
Compound 1 was obtained as yellow amorphous powder. Its
HRESIMS suggested the molecular formula C18H18O3, through the
presence of a peak at m/z 283.1327 [MþH]þ (calcd. for C18H19O3,
283.1329). The 1H NMR spectrum (Table 1) showed signals of two
ortho-coupled aromatic protons (dH 6.70 d and 7.35 d), one aromatic
proton as a singlet (dH 7.11), three methyls (dH 2.48 s, 2.17 s and
2.07 s), and two methylenes (dH 2.73m and 2.53m). These meth-
ylene resonances (H2-9, H2-10) indicated this compound to be a
9,10-dihydrophenanthrene derivative. In the JMOD spectrum, 18
carbon signals was detected closely resembling to juncuenin B,
isolated previously from other Juncus species (J. effusus, J. inﬂexus,
and J. setchuensis) (Table 1) [7,8]. The only difference foundwas that
an acetyl group instead of the vinyl group is linked to the skeleton
at position C-8. In the 1H-1H COSY spectrum, correlations were
observed between dH 6.70 d and dH 7.35 d (H-3eH-4), and dH 2.53m
and 2.73m (H-9eH-10). The location of the methyl groups was
concluded from the HMBC spectrum, as proton signal at dH 2.17 (H3-
11) showed correlations with dC 122.5 (C-1), 138.2 (C-1a), and 156.2
(C-2), and the proton signal at dH 2.07 (H3-12) was found to be in
correlation with dC 117.7 (C-7), 155.5 (C-6) and 143.7 (C-8). The
position of the acetyl group was determined by the HMBC cross-
peaks between methyl signal at dH 2.48 (H3-14) with dC 211.4 (C-
13) and 143.7 (C-8) (Fig. 2). The position of the hydroxy groupswere
indicated by the dC values of C-2 (156.2) and C-6 (155.5). HMBC
correlations of H-5 with C-4a and C-8a also evidenced the sub-
titution of ring C in positions C-6, C-7, and C-8.
The NOESY correlations further conﬁrmed the structure of
compound 1. Overhauser effects were detected between H-3/H-4,
H-4/H-5, H2-10/H3-11, and H3-14/H3-12 (Fig. 3).
All of the above evidence conﬁrmed the planar structure of 1
named as juncatrin A (Fig. 1).
Compound 2 was obtained as yellow amorphous powder. The
1H NMR spectrum of compound 2 was very similar to that of 1, the
only differences were the absence of a methyl signal and the
appearance of a proton resonance at dH 3.78 in 2 proving theFig. 1. Structure of the isolated phenanthrenpresence of a methine (Table 1). Its HRESIMS suggested the mo-
lecular formula C18H16O2, through the presence of a peak at m/z
265.1222 [MþH]þ (calcd. for C18H17O2, 265.1223). Its JMOD spec-
trum (Table 1) showed 18 signals close similar to juncuenin B and
compound 1, with exception of two signals at dC 82.2 and 86.0
which suggested the presence of an acetylene functionality in the
molecule, instead of a vinyl (juncuenin B) or an acetyl group (1). The
location of the methyl groups was concluded from the HMBC
spectrum, as proton signal at dH 2.16 (H3-11) showed correlations
with dC 122.5 (C-1), 138.4 (C-1a), and 156.0 (C-2), whereas the
proton signal at dH 2.33 (H3-12) was found to be in correlation with
dC 126.1 (C-7), 154.7 (C-6) and 122.8 (C-8). The position of the
acetylene group was also determined from the HMBC spectrum, as
proton signal at dH 3.78 (H-14) correlated with dC 122.8 (C-8). The
position of the hydroxy groups (at C-2 and C-6) were determined by
the dC values of C-2 (156.0) and C-6 (154.7). Moreover, HMBC cor-
relations of H-5 with C-4a and C-8a also proved the subtitution of
ring C in positions C-6, C-7, and C-8.
The NOESY cross-peaks between H-3/H-4, H-4/H-5, H-9/H-10,
and H-10/H3-11 conﬁrmed the proposed structure of the molecule.
Based on the above ﬁndings, the structure of this compound (jun-
catrin B) was established as depicted in structural formula 2.
Besides new compounds, juncatrin A (1) and juncatrin B (2), two
dihydrophenanthrenes [juncuenin B (3) and effusol (4)], one
phenanthrene [dehydroeffusol (5)], two ﬂavones [apigenin (6) and
luteolin (7)], the acyclic diterpene phytol (8) and 13(R)-hydroxy-
octadeca-(9Z,11E,15Z)-trienoic acid (9) were also isolated from
J. atratus. Their structures were determined by analysis of MS, 1D
and 2D NMR spectra, and by comparison with literature data
[7e14].
Juncatrins A (1) and B (2) are new natural products, substituted
with an acetyl and an acetylene group at C-8, respectively, instead
of a vinyl group present in juncuenin B (3) at the same position. This
was the ﬁrst time that a phenanthrene with an acetylene moiety
was isolated from natural source. Regarding the isolation yields of
compounds from J. atratus, juncuenin B (3) is the major phenan-
threne asmore than 100mgwas isolated. Most probably, juncatrins
A (1) and B (2) are derived biosynthetically from juncuenin B. All
compounds (1e9) were isolated for the ﬁrst time from J. atratus.
The isolated phenanthrenes (1e5) were tested for their anti-
proliferative activity against three human tumor cell lines [HeLa
and SiHa (cervix adenocarcinoma) and MDA-MB-231 (breast car-
cinoma)] using the MTT test with cisplatin as positive control. HeLa
cell line proved to be the most sensitive with four phenanthreneses (1e5) and other compounds (6e9).
Table 1
NMR spectroscopic data for juncatrins A (1) and B (2), and juncuenin B [500MHz (1H), 125MHz (13C), d in ppm, CD3OD].
No. 1 2 3
dH (J in Hz) dC, type dH (J in Hz) dC, type dH (J in Hz) dC, type
1 122.5, C 122.5, C 122.9, C
1a 138.2, C 138.4, C 139.1, C
2 156.2, C 156.0, C 155.8, C
3 6.70, d (8.4) 114.0, CH 6.70, d (8.3) 113.8, CH 6.69, d (8.4) 113.8, CH
4 7.35, d (8.4) 123.0, CH 7.33, d (8.3) 122.8, CH 7.33, d (8.4) 122.2, CH
4a 127.1, C 127.3, C 126.2, CH
5 7.11, s 110.9, CH 7.11, s 111.3, CH 7.03, s 109.8, CH
5a 135.9, C 135.0, C 138.5, C
6 155.5, C 154.7, C 154.8, C
7 117.7, C 126.1, C 121.4
8 143.7, C 122.8, C 136.9
8a 122.3, C 131.0, C 128.2
9 2.53, m (2H) 26.2, CH2 2.89, dd (6.4, 6.9) (2H) 27.3, CH2 2.65, m (2H) 26.7, CH2
10 2.73, m (2H) 26.2, CH2 2.71, dd (6.5, 6.9) (2H) 26.1, CH2 2.71, m (2H) 26.9, CH2
11 2.17, s 11.6, CH3 2.16, s 11.6, CH3 2.16, s 13.1, CH3
12 2.07, s 12.4, CH3 2.33, s 14.1, CH3 2.15, s 11.6, CH3
13 211.4, C 82.2, C 6.74, dd (11.4, 17.8) 135.0, CH
14 2.48, s 32.9, CH3 3.78, s 86.0, CH 5.54, d (11.3)
5.12, d (17.8)
120.1, CH2
Fig. 2. Diagnostic COSY (▬) and HMBC (H/C) correlations of compound 1.
Fig. 3. NOESY (4) correlations of compound 1.
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and 7.75 mM (5)] than clinically used reference agent cisplatin (IC50
12.43 mM). The compounds with the most pronounced anti-
proliferative action (2e5) was additionally tested against NIH-3T3
mouse ﬁbroblasts in order to obtain preliminary data. It was
found that all of these agents (2e5) exerted only negligible action
(less than 35% inhibitory activity) on ﬁbroblasts even at 30 mM and
therefore, the antiproliferative action of the tested molecules can
be considered cancer selective. Based on the presented results,
some structure-activity relationships could be obtained. Com-
pounds 1e3 differ from each other in only the substituent at C-8.
Since 1 is markedly less effective [on HeLa 55.60± 1.88% (SEM) at
30 mM] than 2 and 3, presence of an acetyl group instead of a vinyl
or an acetylene substituent at the same position seems to be
disadvantageous. In case of compounds 4 and 5, differing only in
the saturation of ring B, the dihydrophenanthrene effusol (4)
proved to be more active. It seems that presence of a methyl group
on ring C has no signiﬁcant effect on the antiproliferative activity of
phenanthrenes against HeLa cell line. Both of other cell lines were
substantially less sensitive. However, compound 2 elicited
remarkable growth inhibition (IC50 11.10 mM) against MDA-MB-
231 cells, which was more pronounced than the effect of cisplatin(19.13 mM). Although 2 exhibited some considerable activity (IC50
25.30 mM) against SiHa cells, it was not comparable to cisplatin
(IC50 7.84 mM).3. Materials and methods
3.1. General
Vacuum liquid chromatography (VLC) was carried out on silica
gel (15 mm, Merck); LiChroprep RP-18 (40e63 mm, Merck) station-
ary phase was used for reversed-phase VLC; column chromatog-
raphy (CC) was performed on polyamide (MP Biomedicals).
Preparative thin-layer chromatography (prep. TLC) was performed
on silica gel 60 F254 plates (Merck) as well as on reversed-phase
silica gel 60 RP-18 F254 plates (Merck). Sephadex LH-20
(25e100 mm, Sigma-Aldrich) was used for gel ﬁltration. HPLC was
carried out on a Waters HPLC, using normal (Phenomenex Luna
Silica (3 mm100 A) and reversed-phase [Phenomenex, Kinetex 5 mm
C18 100A, and LiChrospher LiChroCART 250-4 RP-18e (5 mm)]
columns.
NMR spectra were recorded in CDCl3 and DMSO-d6 on a Bruker
Avance DRX 500 spectrometer at 500MHz (1H) and 125MHz (13C).
The signals of the deuterated solvents were taken as references. The
chemical shift values (d) were given in ppm and coupling constants
(J) are in Hz. Two-dimensional (2D) experiments were performed
with standard Bruker software. In the COSY, HSQC and HMBC ex-
periments, gradient-enhanced versions were used. The high reso-
lution MS spectra were acquired on a Thermo Scientiﬁc Q-Exactive
Plus Orbitrap mass spectrometer equipped with ESI ion source in
positive ionization mode. The resolution was over 1 ppm. The data
were acquired and processed with MassLynx software. All solvents
used for CC were of at least analytical grade (VWR Ltd., Hungary).3.2. Plant material
Juncus atratus Krock. (whole plant) was collected during the
ﬂowering period in 2015, near Bekescsaba (GPS coordinates:
4638’0.80”N; 218’26.71”E) (Hungary). Botanical identiﬁcation of
the plant material was performed by one of the authors Gusztav
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versity, Szarvas, Hungary) and a voucher specimen (No. 877) has
been deposited at the Department of Pharmacognosy, University of
Szeged, Szeged, Hungary.3.3. Extraction and isolation
The air-dried whole plant of J. atratus (3.1 kg) was percolated
with MeOH (60 L) at room temperature. The crude methanol
extract was concentrated to dryness under reduced pressure
(352 g), resolved in water, and subjected to solventesolvent parti-
tioning with dichloromethane (4 1 L) and ethyl acetate (4 1 L),
respectively.
The concentrated dichloromethane-soluble fraction (98.3 g) was
separated by polyamide open column chromatography with
gradient system of MeOHeH2O [1:1, 2:1 (8 L and 10 L, respectively),
each eluent was collected as a fraction (I. and II.)]. The fraction
obtained from the polyamide column with MeOHeH2O 2:1 (II.)
(27.7 g) was subjected to vacuum liquid chromatography (VLC) on
silica gel with a gradient system of cyclohexaneeEtOAceMeOH
[from 98:2:0 to 1:1:1 (1500 mL/eluent), and ﬁnally with MeOH;
volume of collected fractions were 100mL] to yield 15 major frac-
tions (II/1e15). The fractions were combined according to their TLC
patterns.
Fraction II/4 (1.59 g) was separated by reversed-phase VLC,
which was eluted with a gradient system of MeOHeH2O [from 1:1
to 98:2 (500 mL/eluent), and ﬁnally MeOH (200mL); volume of
collected fractions was 50mL] to yield eight subfractions (II/4/1e8).
Subfraction II/4/8 was pure and resulted in compound 6 (10.2mg).
Fraction II/8 (494.0mg) was also puriﬁed by reversed-phase
VLC, using a gradient system of MeOHeH2O [from 1:1 to 95:5
(500 mL/eluent), and ﬁnally MeOH (200mL); volume of collected
fractions was 50mL)] to afford seven subfractions (II/8/1e7). Sub-
fraction II/8/2 was pure and resulted in compound 3 (3.5mg).
Reversed-phase VLC was used for the separation of fraction II/9
(928.3mg). The fraction was eluted by a gradient system of
MeOHeH2O [from 1:1 to 98:2 (500 mL/eluent), and ﬁnally MeOH
(150mL); volume of collected fractions was 50mL] to afford nine
subfractions (II/9/1e9). Further puriﬁcation of subfraction II/9/2 by
reversed-phase HPLC under gradient conditions, using MeOHeH2O
(6:4 to 9:1 in 10min) as mobile phase, at a ﬂow rate of 1.0mL/min
to yield compound 1 (tR¼ 8.6min, 3.2mg). By the use of prepara-
tive TLC on silica gel using cyclohexaneeEtOAceEtOH (60:30:3) as
solvent system compound 4 (3.2mg) was isolated. Subfraction II/9/
5 was pure, and resulted in compound 2 (48.1mg). Subfraction II/9/
6 contained the pure compound 5 (122.6mg).
Fraction II/11 (194.1mg) was also separated by reversed-phase
VLC, using the gradient system of MeOHeH2O [from 1:1 to 98:2
(150 mL/eluent), and ﬁnally MeOH (100mL); volume of collected
fractions was 20mL] to afford ﬁve combined fractions. Fraction II/
11/3 (7.1mg) was puriﬁed by the use of preparative TLC on silica gel
using cyclohexaneeEtOAceEtOH (60:30:3) as solvent system to
yield compound 7 (4.8mg).
Fraction II/13 (1.05 g) was puriﬁed by reversed-phase VLC, using
a gradient system of MeOHeH2O [from 1:1 to 9:1 (500 mL/eluent),
and ﬁnally MeOH (100mL); volume of collected fractions was
50mL] to afford six combined fractions. Fraction II/13/3 (65.9mg)
was puriﬁed by the use of Sephadex LH-20 gel chromatography
using CH2Cl2eMeOH (1:1) as solvent system to yield compounds 8
(22.3mg) and 9 (24.9mg).3.3.1. Juncatrin A (1)
Yellow amorphous solid; 1H and 13C NMR data, see Table 1;
HRESIMS m/z 283.1327 [MþH]þ (calcd. for C18H19O3, 283.1329).3.3.2. Juncatrin B (2)
Yellow amorphous powder; 1H and 13C NMR data, see Table 1;
HRESIMS m/z 265.1222 [MþH]þ, calcd. for C18H17O2, 265.1223).
3.4. Antiproliferative assay
The antiproliferative properties of the isolated phenanthrenes
were determined on a panel of human malignant cell lines isolated
from cervical (HeLa and SiHa) and breast (MDA-MB-231) cancers
purchased from European Collection of Cell Cultures (ECCAC, Sal-
isbury, UK). Cells were cultivated in minimal essential medium
supplementedwith 10% fetal bovine serum,1% non-essential amino
acids and an antibiotic-antimycotic mixture. All media and sup-
plements were obtained from Lonza Group Ltd., (Basel,
Switzerland). Near-conﬂuent cancer cells were seeded onto a 96-
well microplate (5000 cells/well) and, after an overnight standing
medium containing the tested compounds in the concentration
range of 0.1e30 mM, was added. After incubation for 72 h under cell
culture conditions the living cells were assayed by the addition of
20 mL of 5mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution. MTT was converted
by intact mitochondrial enzymes and precipitated as purple crys-
tals during a 4-h contact period. The medium was next removed
and the formazanwas dissolved in 100 mL of DMSO during a 60-min
period of shaking at 37 C. Finally, the reduced MTT was assayed at
545 nm using a microplate reader [15]. In the case of the most
active compounds (i.e. higher than 40% growth inhibition at 10 mM),
the assays were repeated with a set of dilutions, sigmoidal
concentration-response curves were ﬁtted to the determined data
and the IC50 values were calculated by means of GraphPad Prism
5.01 (GraphPad Software, San Diego, CA, USA). All in vitro experi-
ments were carried out on two microplates with ﬁve parallel wells.
Stock solutions of the tested compounds (10mM) were prepared in
DMSO. The highest DMSO content of the medium (0.3%) did not
have any substantial effect on the cell proliferation. Cisplatin
(Ebewe Pharma GmbH, Unterach, Austria) was used as a reference
agent.
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